Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

ALISO VIEJO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.  

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA).  PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.  PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state.    

"The FDA approval of NUEDEXTA marks an important milestone for people living with PBA, an under-recognized and debilitating neurologic condition," said Keith Katkin, president and chief executive officer of Avanir.  "The approval of NUEDEXTA also marks AVANIR's transition toward becoming a commercial enterprise, ready to support the successful launch of the first FDA-approved treatment for PBA. We expect that NUEDEXTA will be available by prescription during the first quarter of 2011."

"This FDA approval represents a significant step forward for people who live with the debilitating effects of PBA," said Dr. Nicholas LaRocca, Vice President of Healthcare Delivery and Policy Research at the National MS Society. "For people who experience unexplained bouts of inappropriate laughing or crying, this new therapy has the potential to substantially help both them and their families."

"Today's approval of NUEDEXTA is a testament to the conviction of the patients and researchers who participated in our studies and represents over 10 years of research and development by our dedicated employees," said Randall Kaye, MD, Chief Medical Officer, AVANIR Pharmaceuticals. "We are very plea
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014  Mylan Inc. (NASDAQ: MYL ) today ... Abbott (NYSE: ABT ) ... developed markets specialty and branded generics business ("the Assets") in ... will receive 105 million shares of the combined company worth ... on Friday, July 11, 2014, representing an approximately 21% ownership ...
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... component of pharmaceutical marketing and, consequently, organizations are ... specifically for patients. As part of ... learned it,s important to educate, communicate and engage ... from disease awareness to patient empowerment. By mapping ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Needles Market 2014-2018" report to their offering. ... hypodermic needle is a hollow needle commonly used with ... or to extract fluids from it. A hypodermic needle ... inject substances that cannot be ingested. Hypodermic needles are ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... Md., May 24, 2007 /PRNewswire-FirstCall/ -- Iomai,Corporation today ... 1 trial of its patch-based needle-free influenza vaccine,before ... live,webcast will be held at 8:30 a.m. Eastern ... Details , To access the live conference call ...
... Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen,Therapeutics, Inc. ... updated Phase 2 clinical trial results,for its ... upcoming,annual meetings of The American Society of ... Society of Gene Therapy (ASGT) in,Seattle., "We ...
Cached Medicine Technology:Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings 2Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings 3
(Date:7/14/2014)... 2014 Physical fitness may buffer some of the adverse ... new study by researchers from the American Cancer Society, ... study appears in the journal Mayo Clinic Proceeding ... and obesity and blood markers associated with cardiovascular disease ... , Sedentary behavior has been linked to an increase ...
(Date:7/14/2014)... July 14, 2014 BCC Research ... SYNTHETIC BIOLOGY: GLOBAL MARKETS , the global ... nearly $11.9 billion in 2018, with a five-year ... products account for the fastest growing segment, with ... Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, energy, ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 The ... Group is now offering Lumineers and porcelain ... extensive procedures that require more preparation and greater loss ... porcelain tooth-shaped shells to conceal visible flaws on the ... Sabbagh-Fard work closely with patients to ensure they offer ...
(Date:7/14/2014)... Bronson Gray HealthDay Reporter ... research suggests that a faltering sense of smell might ... an inexpensive, low-tech smell test could spot who needs ... studies, the decreased ability to identify odors was associated ... to Alzheimer,s disease. "We,re trying to be able ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 (HealthDay ... health issues, but dementia isn,t one of them, according to ... delay dementia, the researchers found. "For those who had ... a later age of developing full-blown dementia compared to those ... Woodruff, an assistant professor of neurology at the Mayo ...
Breaking Medicine News(10 mins):Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3
... of gift-,givers, Valentine,s Day never fails to leave some people ... feel truly special. Of,course roses are the go-to gift that,s ... a new HD TV the best way to tell him, ... reason why gift certificates sales were,second only to clothing during ...
... the International Society for Cardiovascular Translational Research (ISCTR) ... the Journal of Cardiovascular Translational Research (JCTR). ... Inaugural Meeting of the International Society for Cardiovascular ... 2008 in San Diego, CA, USA. The ...
... Features Over 7,400 Furniture Products & Services, ... VWR International, LLC, a,global distributor of scientific ... new 2008-2010 Laboratory Casework and Technical,Furniture Catalog, ... for the research laboratory industry, including customers ...
... living near the World Trade Center had sleeplessness, other ... -- Direct exposure to the World Trade Center ... shows. , The study, by researchers at the Mount ... 116 children averaging about 4 years of age who ...
... Merrill Lynch,s Global Pharmaceutical Conference Feb. ... 5, 2008, ... it will host a conference call and live webcast on,Wednesday, Feb. 27, 2008, ... ended Dec. 31, 2007. The Company also will provide,an operational and integration update ...
... Coherent, Inc.,(Pink Sheets: COHR), today announced its slate ... proxy for the annual meeting scheduled for,March 19, 2008 ... The nominees include current directors Garry Rogerson, John,Ambroseo, John ... first-time,nominees Susan James and Clifford Press., Susan James ...
Cached Medicine News:Health News:Leading Network of Aesthetic Service Providers Offers Unique Gift Ideas for Valentine's Day 2Health News:Springer to publish new society journal in cardiology 2Health News:VWR International Publishes New Laboratory Casework and Technical Furniture Catalog 2Health News:VWR International Publishes New Laboratory Casework and Technical Furniture Catalog 3Health News:9/11 Exposure Linked to Behavior Trouble in Kids 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Coherent Announces Director Slate for Upcoming Annual Meeting 2
Disposable Microscissors: Horizontal, Curved...
Disposable Microscissors: Horizontal, Straight...
Disposable Microscissors: Vertical, 90...
Low profile, sharp-tipped scissors with a vertical cutting action. Excellent for peeling and cutting fine epiretinal membranes....
Medicine Products: